Pardes Biosciences, Inc. Common Stock
PRDS
PRDS was delisted on the 30th of August, 2023.
59 hedge funds and large institutions have $63.9M invested in Pardes Biosciences, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 11 increasing their positions, 23 reducing their positions, and 19 closing their positions.
31% more capital invested
Capital invested by funds: $48.6M → $63.9M (+$15.3M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3% less funds holding
Funds holding: 61 → 59 (-2)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
52% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.01M |
| 2 |
FCMV
Foresite Capital Management V
Larkspur,
California
|
+$1.42M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$1.06M |
| 4 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$883K |
| 5 |
Barclays
London,
United Kingdom
|
+$710K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.6M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.65M |
| 3 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$1.35M |
| 4 |
State Street
Boston,
Massachusetts
|
-$603K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$594K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
76
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$2.81K | -2,125 | Closed |
|
77
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$3K | -1,921 | Closed |
|
|
EI
78
Ellevest Inc
New York
| – | -$40 | -30 | Closed |
|
PRDS Hedge Fund Activity: Q2 2023 in Review
59 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q2 2023, worth a combined $63.9M — up 31% from $48.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PRDS and 17 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 11 added.
The largest buyer was Tang Capital Management, adding an estimated $3.01M. The largest seller was BlackRock, cutting an estimated $2.6M.
- 59 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q2 2023, down from 61 in Q1 2023.
- Funds reported $63.9M of Pardes Biosciences, Inc. Common Stock stock for Q2 2023, up 31% quarter-over-quarter.
- 17 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q2 2023 and 19 closed out, a net change of -2 holders.
- The largest Pardes Biosciences, Inc. Common Stock buyer in Q2 2023 was Tang Capital Management, an estimated $3.01M added.
- The largest Pardes Biosciences, Inc. Common Stock seller in Q2 2023 was BlackRock, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2023.